01052nas a2200229   4500000000100000008004100001260001300042653001100055653001300066100001400079700001400093700001600107700001600123700001200139700001700151700001700168245006200185300001100247490000800258520054200266022001400808       2012                            d  c2012 Dec10aHumans10aVitiligo1 aLotti T M1 aBerti S F1 aHercogova J1 aHuggins R H1 aLee B W1 aJanniger C K1 aSchwartz R A00aVitiligo: recent insights and new therapeutic approaches.  a637-470 v1473 a<p>Vitiligo represents a selective destruction of the melanocytes. It is a relatively common, probably autoimmune disorder that affects people of all backgrounds and both genders. No particular group seems to be preferentially affected. Half of vitiligo patients have an onset before the age of 18 years. In regions where leprosy is endemic, individuals with vitiligo are often stigmatized due to similarities in appearance between the two diseases. We will review this important subject, emphasizing the latest therapeutic advances.</p>  a0392-0488